David A. Wiersma
Senior Associate
Wiersma manages a portfolio of commercialized technologies includes the cisplatinum anticancer agents Platinol® and Paraplatin®, cationic radiopharmaceuticals (Cardiolite®, Myoview™) and the PSA blood test for prostate cancer. His areas of focus at RCT are oncology, pain and metabolic disease.
Professional Experience
Research Corporation Technologies
Senior Associate, 1999–present
Director, Alerion Biomedical Inc., 2004–present
Director, MetaProbe Inc., 1997–2004
Manager, MetaProbe LLC, 1997
Science Advisory Board, Sertoli Technologies Inc., 1996–present
Associate, Life Sciences, 1987–1999
Registered U.S. Patent Agent, 1985–present
Research Corporation, 1984–1987
The University of Arizona
Research Associate, College of Pharmacy, 1982–present
Michigan Drug Detection Center
Laboratory Technologist, Grand Rapids, Michigan, 1975–1977
Education
Michigan State University
Ph.D., Pharmacology
Calvin College
B.S., Biology-Chemistry